The stock of Evgen Pharma PLC (LON:EVG) is a huge mover today! The stock increased 0.43% or GBX 0.1 on November 16, hitting GBX 23.1. Evgen Pharma PLC (LON:EVG) has risen 17.95% since April 18, 2016 and is uptrending. It has outperformed by 13.26% the S&P500.
The move comes after 9 months positive chart setup for the GBX 16.90 million company. It was reported on Nov, 16 by Barchart.com. We have GBX 66.53 PT which if reached, will make LON:EVG worth GBX 31.77 million more.
Evgen Pharma PLC (LON:EVG) Ratings Coverage
Out of 2 analysts covering Evgen Pharma Plc (LON:EVG), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Evgen Pharma Plc has been the topic of 20 analyst reports since October 26, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Northland Capital given on Monday, December 7. The firm earned “Buy” rating on Tuesday, May 31 by Northland Capital. The firm has “Speculative Buy” rating by Beaufort Securities given on Wednesday, June 1. The firm earned “Buy” rating on Tuesday, May 3 by Northland Capital. Northland Capital maintained the shares of EVG in a report on Wednesday, August 17 with “Buy” rating. The stock of Evgen Pharma PLC (LON:EVG) earned “Buy” rating by Northland Capital on Wednesday, January 6. The company was maintained on Friday, September 9 by Northland Capital. The stock has “Buy” rating given by Northland Capital on Wednesday, December 2. Beaufort Securities maintained the stock with “Speculative Buy” rating in Wednesday, May 4 report. The stock of Evgen Pharma PLC (LON:EVG) earned “Hold” rating by Beaufort Securities on Thursday, August 18.
More recent Evgen Pharma PLC (LON:EVG) news were published by: Reuters.com which released: “BRIEF-Evgen Pharma granted orphan drug designation for stabilised sulforap…” on August 24, 2016. Also Businesswire.com published the news titled: “Osteoarthritis Therapeutics Pipeline Review, H2 2015 – Research and Markets” on February 09, 2016. Businesswire.com‘s news article titled: “Global Osteoarthritis Pipeline Report 2016 – Research and Markets” with publication date: May 07, 2014 was also an interesting one.
Evgen Pharma plc is a clinical-stage drug development firm focused on cancer and neurological disease. The company has a market cap of 16.90 million GBP. The Firm operates through the segment of development of pharmaceutical products all within the United Kingdom. It currently has negative earnings. The Company’s pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.